Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication.
Mol Cell
; 81(7): 1548-1552.e4, 2021 04 01.
Article
en En
| MEDLINE
| ID: mdl-33631104
Remdesivir is a nucleoside analog approved by the US FDA for treatment of COVID-19. Here, we present a 3.9-Å-resolution cryo-EM reconstruction of a remdesivir-stalled RNA-dependent RNA polymerase complex, revealing full incorporation of 3 copies of remdesivir monophosphate (RMP) and a partially incorporated fourth RMP in the active site. The structure reveals that RMP blocks RNA translocation after incorporation of 3 bases following RMP, resulting in delayed chain termination, which can guide the rational design of improved antiviral drugs.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Antivirales
/
Replicación Viral
/
ARN Polimerasa Dependiente del ARN
/
ARN Viral
/
Adenosina Monofosfato
/
Alanina
/
SARS-CoV-2
Límite:
Humans
Idioma:
En
Revista:
Mol Cell
Asunto de la revista:
BIOLOGIA MOLECULAR
Año:
2021
Tipo del documento:
Article
País de afiliación:
Estados Unidos